Citius Oncology reported financial results for the fiscal year ended September 30, 2025, and provided a business update.
The company launched LYMPHIR™, a novel IL-2 receptor-directed immunotherapy, in the U.S. in December 2025.
Citius secured access to LYMPHIR in 19 international markets through regional distribution partners via Named Patient Programs.
LYMPHIR™ U.S. Launch
LYMPHIR launched in the U.S. in December 2025 for the treatment of adult patients with relapsed or refractory CTCL.
Strategic Financings
Closed $36 million in gross proceeds from strategic financings, including private placements and public offerings.
Collaboration with Verix
Announced a collaboration with Verix to enhance commercial targeting and provider engagement for LYMPHIR.
Investigator-Initiated Clinical Trial
Announced promising preliminary results of a Phase I clinical trial of pembrolizumab and LYMPHIR in cancer patients.
- Citius shifted from a pre-revenue to a revenue-generating company with the launch of LYMPHIR in the U.S.
- The company strengthened its cash position through strategic financings to support the commercialization of LYMPHIR and international expansion.
- Partnerships with U.S. pharmaceutical wholesalers and distribution partners in international markets enhance market access for LYMPHIR.
Citius Oncology's focus on driving adoption and maximizing commercial efficiency with the launch of LYMPHIR positions the company for growth and sustained value delivery to patients and shareholders.